ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Abelson (ABL) tyrosine kinase inhibitors (TKIs) are effective against chronic myeloid leukemia (CML); however, many patients develop resistance during ABL TKI therapy.